HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement

HIV/AIDS 临床试验单位 (CTU) COVID-19 管理补充资料

• 批准号: 10166401
• 负责人: Joseph J Eron
• 金额: $ 60万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10166401
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Address; Adherence; Adult; Agriculture; Area; Back; Belgium; COVID-19; COVID-19 pandemic; Caring; Cessation of life; Childhood; China; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Color; Communication; Communities; Contact Tracing; Containment; Coronavirus; Country; County; Data; Detection; Diagnosis; Diagnostic; Disease; Disease Outbreaks; Doctor of Philosophy; Emerging Communicable Diseases; Ensure; Equipment; Evaluation; Farming environment; Finland; General Population; Geography; Germany; Goals; HIV; HIV Infections; Health; Healthcare; Home environment; Hospitalization; Human; Incidence; Individual; Industry; Infection; Infection Control; Infrastructure; Institutes; Laboratories; Leadership; Life; Living Standards; Malawi; Meat; Modeling; Molecular; National Institute of Allergy and Infectious Disease; North Carolina; Performance; Pharmacy facility; Planets; Plants; Play; Population; Populations at Risk; Positioning Attribute; Prevention; Prevention strategy; Principal Investigator; Protocols documentation; Public Health; Quarantine; Reporting; Research; Resources; Role; Rural; Senior Scientist; Site; Social Distance; South Korea; Southeastern Asia; Southern Africa; Structure; Taiwan; Tennessee; Testing; Therapeutic; Time; Unemployment; United States National Institutes of Health; Universities; Vaccines; Vietnam; Virus; Work; authority; clinical research site; data management; experience; global health; improved; innovation; microbicide; operation; pandemic disease; preservation; prevent; quality assurance; racial and ethnic disparities; response; rural area; rural counties; screening; transmission process; urban area

Project Summary/Abstract The University of North Carolina (UNC) Global HIV Clinical Trials Unit (CTU) has a well established track record of high-quality, innovative clinical research, strong scientific leadership (both in and outside the NIH HIV/AIDS Networks), and access to critically important infected and at-risk populations in the Southeastern US, Southeast Asia and in Southern Africa. Drawn from a diverse team of clinical innvestigators spanning two continents, our is led by experienced principal investigators (Joseph Eron MD and Mina Hosseinipour MD) and will support all 5 NIH HIV Clinical Trials Networks: Adult Therapeutic Strategies, Strategies to Address HIV and HIV- associated Infections in Pediatric and Maternal Populations, Integrated HIV Prevention Strategies, Microbicide Strategies, and Vaccine Strategies to Prevent HIV Infection. The Clinical Research Sites (CRS) include Chapel Hill CRS led by David Wohl MD (Adult Therapeutic Strategies, Integrated Prevention, Microbicide and Vaccine), Greensboro CRS led by Cornelius Van Dam MD PhD (Adult Therapeutic Strategy and Integrated Prevention), Malawi CRS led by Lameck Chinula MD (all 5 Networks) and Vietnam (protocol specific site) led by Vivian Go. Supporting this leadership is a well-organized research team, comprising global experts and site collaborators who will work to execute the network scientific agendas. The CTU has also assembled a diverse group of senior scientists and public health officials to serve on our Scientific and Strategic Advisory Group. The CTU administration incorporates a highly organized structure that will be responsive to our experienced research teams across the CRS and will provide ongoing evaluation to ensure optimal performance and efficiency. The CTU is supported by state-of-the-art communications and outstanding laboratory, pharmacy, quality assurance, data management and regulatory support. With its robust administrative framework, the UNC Global HIV CTU is optimally positioned to provide scientific leadership and clinical trials infrastructure to advance the field of agenda of the NIAID HIV networks and emerging infectious disease such as the SARS-CoV-2 pandemic.

项目总结/摘要 北卡罗来纳州大学（UNC）全球艾滋病毒临床试验部门（CTU）拥有良好的 建立了高质量、创新临床研究的良好记录，强大的科学领导力 (both在NIH艾滋病毒/艾滋病网络内外），并获得至关重要的感染者和 美国东南部、东南亚和南部非洲的高危人群。来自 我们的临床研究团队横跨两大洲，由经验丰富的 首席研究员（Joseph Eron MD和Mina Hosseinipour MD），并将支持所有5个NIH 艾滋病毒临床试验网络：成人治疗策略，解决艾滋病毒和艾滋病的策略- 儿童和孕产妇人群中的相关感染，艾滋病毒综合预防 预防艾滋病毒感染的战略、杀微生物剂战略和疫苗战略。临床 研究中心（CRS）包括由大卫沃尔医学博士（成人治疗）领导的查佩尔山CRS 战略，综合预防，杀微生物剂和疫苗），格林斯伯勒CRS由科尼利厄斯领导 货车达姆医学博士（成人治疗战略和综合预防），马拉维CRS， Lameck Chinula MD（所有5个网络）和越南（协议特定站点），由Vivian Go领导。 支持这一领导地位的是一个组织良好的研究团队，该团队由全球专家和现场组成 将致力于执行网络科学议程的合作者。反恐组还 召集了一批不同的高级科学家和公共卫生官员， 科学和战略咨询小组。反恐组的管理层 组织结构，将响应我们经验丰富的研究团队在整个CRS 并将提供持续评估，以确保最佳业绩和效率。职工盟 由最先进的通信和优秀的实验室，药房，质量支持 保证、数据管理和监管支持。凭借其强有力的行政框架， 全球艾滋病病毒CTU处于提供科学领导和临床 试验基础设施，以推进NIAID艾滋病毒网络的议程领域， 传染病，如SARS-CoV-2大流行。